Enanta Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $12.52
- Today's High:
- $13.29
- Open Price:
- $12.52
- 52W Low:
- $22.8
- 52W High:
- $76.36
- Prev. Close:
- $12.47
- Volume:
- 544654
Company Statistics
- Market Cap.:
- $539.23 million
- Book Value:
- 12.798
- Revenue TTM:
- $81.18 million
- Operating Margin TTM:
- -158.98%
- Gross Profit TTM:
- $86.16 million
- Profit Margin:
- -153.61%
- Return on Assets TTM:
- -22%
- Return on Equity TTM:
- -39.71%
Company Profile
Enanta Pharmaceuticals Inc had its IPO on 2013-03-21 under the ticker symbol ENTA.
The company operates in the Healthcare sector and Biotechnology industry. Enanta Pharmaceuticals Inc has a staff strength of 160 employees.
Stock update
Shares of Enanta Pharmaceuticals Inc opened at $12.52 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $12.52 - $13.29, and closed at $13.07.
This is a +4.81% increase from the previous day's closing price.
A total volume of 544,654 shares were traded at the close of the day’s session.
In the last one week, shares of Enanta Pharmaceuticals Inc have slipped by -11.33%.
Enanta Pharmaceuticals Inc's Key Ratios
Enanta Pharmaceuticals Inc has a market cap of $539.23 million, indicating a price to book ratio of 2.8795 and a price to sales ratio of 10.5822.
In the last 12-months Enanta Pharmaceuticals Inc’s revenue was $81.18 million with a gross profit of $86.16 million and an EBITDA of $-126630000. The EBITDA ratio measures Enanta Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Enanta Pharmaceuticals Inc’s operating margin was -158.98% while its return on assets stood at -22% with a return of equity of -39.71%.
In Q1, Enanta Pharmaceuticals Inc’s quarterly earnings growth was a negative -66.2% while revenue growth was a negative 4.9%.
Enanta Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-6.53 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Enanta Pharmaceuticals Inc’s profitability.
Enanta Pharmaceuticals Inc stock is trading at a EV to sales ratio of 8.1396 and a EV to EBITDA ratio of -5.8021. Its price to sales ratio in the trailing 12-months stood at 10.5822.
Enanta Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $326.45 million
- Total Liabilities
- $32.17 million
- Operating Cash Flow
- $46.77 million
- Capital Expenditure
- $2.38 million
- Dividend Payout Ratio
- 0%
Enanta Pharmaceuticals Inc ended 2023 with $326.45 million in total assets and $0 in total liabilities. Its intangible assets were valued at $326.45 million while shareholder equity stood at $269.38 million.
Enanta Pharmaceuticals Inc ended 2023 with $0 in deferred long-term liabilities, $32.17 million in other current liabilities, 210000.00 in common stock, $-139823000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $73.18 million and cash and short-term investments were $210.08 million. The company’s total short-term debt was $4,923,000 while long-term debt stood at $0.
Enanta Pharmaceuticals Inc’s total current assets stands at $271.14 million while long-term investments were $15.04 million and short-term investments were $136.91 million. Its net receivables were $46.57 million compared to accounts payable of $11.76 million and inventory worth $0.
In 2023, Enanta Pharmaceuticals Inc's operating cash flow was $46.77 million while its capital expenditure stood at $2.38 million.
Comparatively, Enanta Pharmaceuticals Inc paid $0 in dividends in 2023.
Other key metrics
- Current Trading Price
- $13.07
- 52-Week High
- $76.36
- 52-Week Low
- $22.8
- Analyst Target Price
- $42.13
Enanta Pharmaceuticals Inc stock is currently trading at $13.07 per share. It touched a 52-week high of $76.36 and a 52-week low of $76.36. Analysts tracking the stock have a 12-month average target price of $42.13.
Its 50-day moving average was $17.13 and 200-day moving average was $33.97 The short ratio stood at 3.15 indicating a short percent outstanding of 0%.
Around 659.4% of the company’s stock are held by insiders while 9365.7% are held by institutions.
Frequently Asked Questions About Enanta Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.